Project Grant K08AI199057
- Federal Grant Award Summary Brigham & Women's Hospital Inc. (Department of Faulkner Pathology) received a $193,600 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026 through March 31, 2031. The award funds investigator-initiated biomedical research to define the T cell state that sustains chronic allergic disease, with emphasis on understanding the...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $3.08M Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 5, 2026, with completion targeted for January 31, 2030. This research initiative investigates the mechanisms sustaining pathogenic TH2 (Type 2 T helper cell) multipotent progenitor populations in chronic type 2 inflammatory diseases,...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc., through the Department of Faulkner Pathology, received a $778,143 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) awarded June 3, 2026, with a completion date of May 31, 2031. This five-year research initiative investigates the regulation of naive follicular B cell polyreactivity and how antibody-producing B cells...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $855,342 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 12, 2026, with a completion date of May 31, 2031. The award supports investigator-initiated biomedical research examining the pathogenic roles of follicular helper T (Tfh) cells in systemic lupus erythematosus (SLE), a prototypical...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Brigham & Women's Hospital Inc. a Project Grant totaling $2,472,443 under the Allergy and Infectious Diseases Research program (CFDA 93.855) beginning June 1, 2026, with completion targeted for April 30, 2031. This research initiative investigates neutrophil heterogeneity in immune regulation through multiple integrated projects led by principal investigators examining distinct neutrophil...
- Federal Grant Award Summary Brigham & Women's Hospital Inc., operating as the Department of Faulkner Pathology in Boston, Massachusetts, received a $823,143 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) awarded February 6, 2026, with a completion date of January 31, 2031. The grant supports basic science research investigating regulatory T cell (Treg) defects in amyotrophic lateral...
- Federal Grant Award Summary Brigham & Women's Hospital Inc., operating through its Department of Faulkner Pathology in Boston, MA, received a $194,400 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 12, 2025, with completion targeted for August 31, 2030. This five-year research career development award supports a comprehensive investigation of antibody-dependent...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc., Department of Faulkner Pathology, received a $194,400 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 15, 2025, with completion targeted for August 31, 2029. The award supports research examining vaccine immunogenicity and adoptive transfer of immunity in allogeneic hematopoietic stem cell...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Feinstein Institutes for Medical Research a $460,625 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 10, 2026, with a completion date of January 31, 2028. This award supports investigator-initiated biomedical research focused on understanding the maturation and maintenance of the germinal center niche, specifically examining follicular...
- Federal Grant Award Summary Award Details: Massachusetts General Hospital (The General Hospital Corporation) received a $250,000 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 1, 2025, with completion anticipated July 31, 2026. Research Objectives and Deliverables: This grant supports biomedical research investigating lung-resident memory T helper type 2 (TH2) cells as novel...
Brigham and Women's Hospital, through its Department of Faulkner Pathology, received a $199,000 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 12, 2026 through May 31, 2031. This award supports investigator-initiated biomedical research examining the role of lung T follicular helper (TFH) cell subsets in airway-localized immunoglobulin E (IgE) production and allergic airway disease pathogenesis. The research will generate scientific knowledge regarding the developmental origin, phenotype, effector function, and spatial organization of TFH and TFH13 cells within lung tissue, with particular focus on their contribution to local IgE production and regional immunopathology. The deliverables from this award include characterization studies of lung-resident TFH and TFH13 cell populations using novel mouse models and human clinical cohorts, identification of allergen-specific IgE B cell differentiation trajectories and pathogenic potential within lung tissue, and elucidation of cellular and anatomical mechanisms underlying localized IgE responses in allergic airway disease. These research products are intended to advance understanding of allergic disease mechanisms and inform development of targeted therapeutic interventions for asthma and related allergic conditions.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $199.0k | 6/16/26 |